Table 2

Baseline patient characteristics.

Panel A

Panel B


Prednisone 15 mg Number = 8

Placebo Number = 10

Prednisone 7.5 mg Number = 18

Placebo Number = 9


Gender, number (%)

Female

6 (75.0)

5 (50.0)

12 (66.7)

6 (66.7)

Male

2 (25.0)

5 (50.0)

6 (33.3)

3 (33.3)

Age, years

Mean (SD)

61.6 (6.5)

58.4 (12.8)

57.9 (13.3)

55.1 (12.8)

Range

48 to 69

45 to 86

37 to 81

32 to 71

Race, number (%)

Asian

0 (0.0)

3 (30.0)

2 (11.1)

3 (33.3)

Black

0 (0.0)

1 (10.0)

4 (22.1)

0 (0.0)

White

8 (100.0)

6 (60.0)

12 (66.7)

6 (66.7)

10MCP Trans PDA, mean (SD)

9.48 (6.44)

10.55 (9.54)

8.31 (8.66)

9.78 (7.28)

DAS28(CRP), mean (SD)

5.2 (1.3)

5.5 (1.6)

5.3 (1.2)

5.6 (1.8)

Number of tender joints, mean (SD)

10.9 (7.4)

13 (10.1)

13.6 (8.6)

18.4 (10.1)

Number of swollen joints, mean (SD)

10.1 (5.4)

12.5 (8.7)

11.3 (5.6)

16.3 (8.6)

CRP (mg/L), median (quartiles)

8.4 (4.2-25.3)

14.0 (3.5-37.2)

6.9 (1.7-14.6)

3.7 (0.7 - 11.4)

Patients with positive rheumatoid factora, number (%)

6 (75.0)

6 (60.0)

16 (88.9)

6 (66.7)


In this instance, the 10MCP Trans PDA for Panel A used data from all three baseline scans. There were no statistically significant differences, P >0.05, between groups based on nonparametric Wilcoxon and t-tests. aPositive rheumatoid factor was defined as rheumatoid factor >= 12 KU/L, the reference range for Quest assay. CRP, C-reactive protein; DAS28, Disease Activity Score in 28 Joints; MCP, metacarpophalangeal joint; PDA; Power Doppler Area; SD, standard deviation.

Seymour et al. Arthritis Research & Therapy 2012 14:R198   doi:10.1186/ar4034

Open Data